CTOs on the Move

Gritstone Oncology

www.gritstoneoncology.com

 
Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Javier Montes
Associate Director IT Operations Profile
Jayant Aphale
Executive Vice President of Technical Operations Profile

Funding

Gritstone Oncology raised $102M on 10/20/2015
Gritstone Oncology raised $92.7M on 09/07/2017
Gritstone Oncology raised $125M on 12/28/2020

Similar Companies

Health Diagnostic Laboratory

Health Diagnostic Laboratory is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Geotechnics Inc

Geotechnics Inc is a East Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biogenex

Biogenex is a San Ramon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Reliability Labs Inc

American Reliability Labs Inc is a Malden, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zai Lab

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Headquartered in Shanghai since our founding in 2014, our experienced team has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on our extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development. Through these partnerships, Zai Lab has built the strongest late stage oncology portfolio with global first-in-class and/or best-in-class profile, among innovative Chinese biotech companies. We are further supplementing our pipeline with an in-house discovery effort aiming to produce 1-2 global INDs per year. Zai Lab is rapidly expanding into a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing innovative medicines. To that end, we have built our internal R&D center to advance our discovery pipeline, a strong clinical development and operations team, and our own manufacturing facilities in China. We have also established a highly specialized commercial team to support marketing of our innovative products in China. We believe this integrated approach will provide sustainable competitive advantages for Zai Lab. Zai Lab was successfully listed on the Nasdaq Stock Market in September 2017. Since then, Zai Lab significantly expanded with several offices across China and opened its U.S. headquarters in San Francisco in December 2018. As of December 2019, the Company has a global team of approximately 700 employees.